Medipharm Labs Corp T.LABS

Key Point here from DEA because LABS has already been

[subaru1i]

involved with the DEA to export clinical trial materials for the NIH.


DEA Calls for Production of More Cannabis Compounds and Psilocybin – The Drug Enforcement Administration (DEA) has finalized significant increases in its 2024 production quotas for cannabis compounds and psychedelics. Responding to comments from registered manufacturers, the final order includes even higher production quotas for several Schedule I substances—including delta-9 THC and all other tetrahydrocannabinol–than initially proposed by the agency. According to the DEA, such increases were necessary to “allow for manufacturers to meet medical and scientific needs.”

[subaru1i]

5-Methoxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 25 5-Methoxy-N,N-diisopropyltryptamine .................................................................................................................................................. 25 5-Methoxy-N,N-dimethyltryptamine

[subaru1i]

Issue: DEA received comments from three DEA-registered manufacturers regarding 3 different schedule I and II controlled substances, requesting that the proposed APQ for dexmethylphenidate (for conversion), lisdexamfetamine, and psilocybin be established at sufficient levels to allow for manufacturers to meet medical and scientific needs. DEA also received additional or revised quota applications